GleamWall
中文EN

YBGJ Yubo International Biotech Ltd

Electromedical & Electrotherapeutic Apparatus · OTC · SEC CIK 895464 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY68,727.8%
TTM net income YoY31.6%
TTM EPS YoY100.0%
Revenue 3-yr CAGR-73.4%
Net income 3-yr CAGR—

Margins

Gross margin66.1%
Operating margin-8,232.7%
Net margin-7,171.5%
FCF margin—
EBITDA margin-7,667.1%

Returns

ROE—
ROA-110.4%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets544.9%
Debt / equity—
Current ratio0.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.47x
Accruals ratio-58.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$12,353$3,470
Cost of revenue$4,188$822
Gross profit$8,165$2,648
Operating income-$1.19M-$1.77M
Pretax income-$1.19M-$1.98M
Income tax$0$0
Net income-$1.08M-$1.78M
EBITDA-$1.02M-$1.60M
EPS (diluted)-0.01-0.02
Weighted avg. shares (diluted)139.64M119.82M
Banking
Net interest income—$50
Deposits$71,135$68,500
Balance sheet
Cash & equivalents$8,062$7,015
Receivables$138,043$164,984
Inventory$24,034$36,953
Current assets$667,512$682,751
PP&E, net$43,030$205,911
Intangibles$42,080$50,523
Total assets$847,094$1.53M
Current liabilities$2.79M$4.72M
Total liabilities$2.79M$4.83M
Shareholders' equity-$1.95M-$3.42M
Cash flow statement
Operating cash flow-$842,802-$1.34M
Investing cash flow$0$118,431
Financing cash flow$849,545$1.41M
Depreciation & amortization$167,581$169,875

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.